It is well known that there is a multitude of cancer subtypes, each characterized by specific anomalies that evolve during cancer progression. Better knowledge of these anomalies and their consequences on mechanisms of cancer development has made it possible to implement new treatments. These treatments will specifically target the disturbances caused by these anomalies.
Initial tumor biopsies performed from primary cancer provide important information that is used to establish cancer diagnostic and permit oncologists choosing initial clinical strategy. However, after tumor ablation, there is no tumor material left for cancer evolution follow-up.
Circulating tumor cells are involved in the dissemination of tumor cells from the primary tumor to distant sites through the bloodstream. The emergence of precision medicine technologies enables full molecular analysis even if only a few cells are available. This technical evolution will make possible the use of CTC for providing the same level of information as that obtained with the primary biopsy.
This opens very promising opportunities since CTCs can be obtained from a simple blood sample. The process is thus noninvasive and safe for patient’s status follow-up. This contrasts with routine tumor tissue biopsies that need potentially harmful surgical intervention.
ScreenCell technology isolates intact and living CTCs; we have thus access to a full range of technologies that characterize the molecular and cytological specificity of these tumor cells.